☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
second line
Eli Lilly's Cyramza (ramucirumab) Receives FDA's Approval as a Second-line Treatment in Patients with High AFP Hepatocellular Carc...
May 13, 2019
Load more...
Back to Home